Remigiusz Flakus

Remigiusz Flakus

Auto-generated profile, based on publicly available information

Remigiusz Flakus

Military Clinical Hospital with Polyclinic in Wrocław, Wrocław, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ASAleksandra Sokół
Aleksandra Sokół
KGKarolina Glajcar
Karolina Glajcar
RFRemigiusz Flakus
Remigiusz Flakus
ŻKŻaneta Kania
Żaneta Kania
WPWeronika Perczyńska
Weronika Perczyńska
MCMarianna Chmiel
Marianna Chmiel
Introduction: Physical activity during pregnancy is attracting increasing interest among women, doctors and researchers. In recent years, there has been a growing body of research highlighting the positive effects of physical activity during this period. Contrary to earlier beliefs, physical activity is not only safe, but also recommended. The aim of this review is to analyse the current scientific evidence on the safety and benefits of exercise during pregnancy and to provide recommendations on the type and intensity of activity. Methods: A comprehensive search of the scientific literature was conducted using PubMed and Google Scholar, taking into account publications published since 2017. Keywords included: "physical activity", "pregnancy", "healthy pregnant woman", "exercise" and "pregnant exercises". Conclusions: A review of the scientific literature from the last eight years shows that regular, moderate physical activity has a number of health benefits for mother and baby, provided there are no medical contraindications. Promoting individualized, supervised exercise and education for both expectant mothers and healthcare providers should be a key element of prenatal care.

30 March 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
GKGabriela Kapłon
Gabriela Kapłon
KKKamila Kapłon
Kamila Kapłon
BTBarbara Tomaszek
Barbara Tomaszek
ABAleksandra Blok
Aleksandra Blok
DGDominika Gieroba
Dominika Gieroba
KGKarolina Glajcar
Karolina Glajcar
Background: Cancer is a leading cause of mortality worldwide and is associated with the accumulation of DNA damage, disruptions in cell cycle control, and loss of genomic stability. Statistical intuition suggests that large body size or long lifespan should increase cancer risk. However, empirical observations contradict this assumption. Species such as elephants, bowhead whales, and naked mole rats do not exhibit a proportionally higher incidence of cancer, a phenomenon known as Peto's paradox. Aim: This study aimed to compare mechanisms of cancer resistance in selected mammalian species characterized by large body size or exceptional longevity, with particular emphasis on elephants, bowhead whales, and naked mole rats. The analysis focused on DNA repair pathways, cell cycle regulation, and tumor suppressor proteins, including p53 and CIRBP. Materials and Methods: A literature review was conducted using the PubMed, ScienceDirect, Encyclopedia Britannica, Springer and the World Health Organization. The search included the terms “CIRBP,” “Peto's paradox,” “p53 protein,” “DNA repair pathways,” “Bowhead whale,” “Cancer Resistance in Elephants,” and “Naked Mole Rat.” Only publications in English were included. Conclusions: Comparative analysis revealed that evolution has led to diverse and effective mechanisms limiting carcinogenesis. Of particular significance is the identification of the CIRBP protein in the bowhead whale as a factor enhancing the efficiency of DNA repair, highlighting the translational potential of comparative oncology for cancer prevention and therapy.

9 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JSJulia Szczotka
Julia Szczotka
GSGabriela Szpila
Gabriela Szpila
RFRemigiusz Flakus
Remigiusz Flakus
ŻKŻaneta Kania
Żaneta Kania
GKGabriela Kapłon
Gabriela Kapłon
KGKarolina Glajcar
Karolina Glajcar
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide and constitutes a significant public health concern due to its rising incidence and the absence of curative therapies. This review synthesizes recent pharmacological progress in the treatment of AD, with particular emphasis on emerging therapeutic strategies and investigational drug classes. The analysis draws on clinical trial data, regulatory documents, and peer-reviewed literature published between 2017 and 2025, identified through major scientific databases including PubMed, Scopus, and ClinicalTrials.gov. The most promising advances are associated with monoclonal antibodies directed against amyloid-beta pathology, such as aducanumab, lecanemab, and donanemab, which show potential to modify disease progression but also raise concerns related to efficacy, safety, and regulatory approval. Additional innovative approaches, including tau-targeted therapies, gene editing technologies such as CRISPR-Cas9, and RNA interference (RNAi), present new therapeutic opportunities, though they remain limited by challenges such as amyloid-related imaging abnormalities (ARIA), restricted delivery across the blood–brain barrier, and uncertainties regarding long-term clinical outcomes. While currently available pharmacological options are insufficient to halt or reverse AD, recent advancements, particularly in antibody-based therapies, represent an important step toward a new therapeutic era. Nevertheless, cautious interpretation of preliminary findings and rigorous clinical validation remain essential before these strategies can be translated into widespread clinical practice.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
DGDominika Gieroba
Dominika Gieroba
AKAnna Kamieniak
Anna Kamieniak
WPWeronika Perczyńska
Weronika Perczyńska
GKGabriela Kapłon
Gabriela Kapłon
JSJulia Szczotka
Julia Szczotka
KGKarolina Glajcar
Karolina Glajcar
Research objectives: Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract with a complex pathogenesis in which the brain-gut axis is disrupted. Due to the multifactorial basis of the disorder, it is very important to combine pharmacological and psychological treatment with dietary treatment to alleviate patients' symptoms. The purpose of this dissertation was to present the effectiveness of pharmacological, dietary, psychological and novel treatments currently at research level in patients with irritable bowel syndrome. Method: In order to evaluate the effectiveness of various therapies in IBS, a systematic review was conducted. It covers articles from years 2020 - 2024, that were published in PubMed, MDPI, and Sage Journals databases. Key Findings: The treatment of irritable bowel syndrome requires a combination of different therapies to achieve an effective therapeutic effect. There is no specific form of treatment to cure IBS. Conclusions: Currently it is only possible to alleviate the discomfort and improve the quality of life by combining the various methods available. The method that seems to be the most effective is a combination of pharmacological, dietary and psychological treatment. Pharmacological therapy makes it possible to alleviate pain, constipation or diarrhea. The introduction of the FODMAP diet eliminates factors that adversely affect the intestinal microbiota, and psychotherapy, combined with pharmacological treatment of depression and anxiety, alters thinking and synthesizes hormones that affect the gut-brain axis. Alternative treatments are currently being researched, but it will take time and further research before these methods can be incorporated into standard therapy.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
MCMarianna Chmiel
Marianna Chmiel
ATArtur Tumiński
Artur Tumiński
GKGabriela Kapłon
Gabriela Kapłon
WPWeronika Perczyńska
Weronika Perczyńska
JSJulia Szczotka
Julia Szczotka
DGDominika Gieroba
Dominika Gieroba
Introduction and objective: Haemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome that may follow viral infections. We present a case of a 12-month-old boy who developed disseminated intravascular coagulation (DIC) and fulfilled HLH diagnostic criteria following influenza A virus infection. Extensive diagnostics excluded a genetic cause. Treatment based on the HLH-2018 protocol led to full recovery. This case emphasizes the importance of considering HLH in infants with severe systemic inflammation and coagulopathy, even in the absence of EBV infection. Early recognition and appropriate therapy are essential to improve outcomes. Results. This case report describes a 12-month-old boy with haemophagocytic lymphohistiocytosis (HLH) and disseminated intravascular coagulation (DIC) following influenza A infection. Despite negative genetic testing, the patient met HLH diagnostic criteria. Treatment per HLH-2018 protocol was successful. The case underscores the importance of early recognition of HLH in viral infections beyond Epstein-Barr virus.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
GKGabriela Kapłon
Gabriela Kapłon
WPWeronika Perczyńska
Weronika Perczyńska
JSJulia Szczotka
Julia Szczotka
GSGabriela Szpila
Gabriela Szpila
RFRemigiusz Flakus
Remigiusz Flakus
MCMarianna Chmiel
Marianna Chmiel
Background: Hashimoto’s thyroiditis is one of the most common autoimmune diseases, with a noticeable increase in incidence observed in recent years. Despite its high prevalence, current treatment options remain limited and primarily focus on managing the consequences rather than addressing the underlying causes of the condition. Metformin, although primarily prescribed for diabetes, has demonstrated promising anti-inflammatory and immunoregulatory properties in several autoimmune disease models. Aim: This review aims to evaluate the potential role of metformin in the management of Hashimoto’s thyroiditis, with a particular focus on its effects on immune regulation and thyroid function. Methods: An electronic literature search was performed using PubMed, Cochrane Library, ScienceDirect and Evidence‑Based Medicine Reviews. Search terms included ‘Metformin’, ‘Hashimoto disease’, ‘Thyroiditis’, ‘Thyroid’, ‘autoimmune disease’ as keywords. Only articles in English were considered. Conclusions: Preliminary data suggest that metformin, through its anti-inflammatory properties and modulation of AMPK/mTOR pathways, may influence immune responses in Hashimoto’s thyroiditis. Despite promising preclinical findings, further clinical trials involving human participants are required to evaluate its therapeutic efficacy and safety in this context.